|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | BL02U1:the relocated macromolecular crystallography beamline at the Shanghai Synchrotron Radiation Facility显示文摘Macromolecular crystallography beamline BL17U1 at the Shanghai Synchrotron Radiation Facility has been relocated,upgraded,and given a new ID(BL02U1).It now delivers X-rays in the energy range of 6–16 keV,with a focused beam of 11.6μm×4.8μm and photon flux greater than 1012 phs/s.The high credibility and stability of the beam and good timing synchronization of the equipment significantly improve the experimental efficiency.Since June 2021,when it officially opened to users,over 4200 h of beamtime have been provided to over 200 research groups to collect data at the beamline.Its good performance and stable operation have led to the resolution of several structures based on data collected at the beamline. | Ke Liu Huan Zhou Qin Xu Hua‑Ting Kong Kun‑Hao Zhang Wei‑Wei Wang Min‑Jun Li Zhi‑Jun Wang Qiang‑Yan Pan Xing‑Ya Wang Feng Yu Qi‑Sheng Wang | 2023 | Nuclear Science and Techniques2023，34，12： | 0 |
| 2 | The biosafety level-2 macromolecular crystallography beamline(BL10U2)at the Shanghai Synchrotron Radiation Facility显示文摘BL10U2 is an undulator-based macromolecular crystallography(MX)beamline located at the 3.5-GeV Shanghai Synchrotron Radiation Facility.BL10U2 is specifically designed for conducting routine and biosafety level-2(BSL-2)MX experiments utilizing high-flux tunable X-rays with energies from 7 to 18 keV,providing a beam spot size of 20μm(horizontal)×10μm(vertical)at the sample point.Certification by the Shanghai Pudong Municipal Health Commission confirmed the capability to perform BSL-2 MX experiments.The beamline is currently equipped with an Eiger X 16 M detector and two newly developed in-house high-precision diffractometers that can be switched to perform conventional or in situ crystal diffraction experiments.An automatic sample changer developed in-house allows fast sample exchange in less than 30 s,supporting high-throughput MX experimentation and rapid crystal screening.Data collection from both the diffractometer and detector was controlled by an in-house developed data collection software(Finback)with a user-friendly interface for convenient operation.This study presents a comprehensive overview of the facilities,experimental methods,and performance characteristics of the BL10U2 beamline. | Qin Xu Hua‑Ting Kong Ke Liu Huan Zhou Kun‑Hao Zhang Wei‑Wei Wang Min‑Jun Li Qiang‑Yan Pan Xing‑Ya Wang Yu‑Zhu Wang Feng Yu Xing‑Yu Gao Qi‑Sheng Wang | 2023 | Nuclear Science and Techniques2023，34，12： | 0 |
| 3 | 血浆Epstein-Barr病毒DNA对鼻咽癌患者颈部淋巴结残留的诊断和预后价值:一项回顾性研究显示文摘背景与目的目前,诊断鼻咽癌(nasopharyngeal carcinoma,NPC)患者进行联合化疗的根治性放疗后是否出现颈部淋巴结残留及治疗是具有挑战性的。我们分析了颈部淋巴结残留NPC患者的预后,并评估了Epstein-Barr病毒(Epstein-Barr virus,EBV)DNA对这些患者的诊断和预后的价值。方法本研究纳入了82例NPC患者,他们在完成抗肿瘤治疗后被诊断出疑似发生颈部淋巴结残留。在开始进行治疗和颈部清扫之前,使用定量聚合酶链反应(quantitative polymerase chain reaction,qPCR)检测患者血浆EBV DNA水平。21例患者接受了细针抽吸细胞学检查(fine needle aspiration cytology,FNAC)。所有患者均接受了颈部清扫术和术后病理检查,以明确颈淋巴结的性质。采用Kaplan-Meier法计算总生存期(overall survival,OS)、无进展生存期(progression-free survival,PFS)、无远处转移生存期(distant metastasis-free survival,DMFS)和局部区域无复发生存期(locoregional relapse-free survival,LRRFS),并使用log-rank检验进行比较。采用Cox比例风险模型计算置信区间(confidenceinterval,CI)为95%时的风险比(hazardratio,HR)。采用多变量分析估计潜在预后因素对生存的影响。结果中位随访52.6个月后,与术后病理结果阴性的患者相比,结果阳性的颈淋巴结残留患者的3年PFS率显著降低(49.9%vs.83.3%,P=0.008)。在颈淋巴结残留的鼻咽癌患者中,术前血浆EBV DNA>0拷贝/mL的患者的3年PFS率低于未检测到EBV DNA的患者(43.7%vs.61.1%,P=0.031)。此外,将FNAC与术前EBVDNA检测相结合可提高诊断灵敏度。多变量分析显示,术后颈部淋巴结残留病理结果阳性是PFS的独立预后因素,术前可检测到血浆EBV DNA是OS的独立预后因素。结论采用FNAC联合术前EBV DNA检测可提高对颈部淋巴结残留的NPC的诊断敏感性。与未检出EBV DNA的患者相比,术前检出血浆EBV DNA的患者预后较差,并且可能需要更积极的治疗方案。 | Sai‑Lan Liu Xue‑Song Sun Xiao‑Yun Li Lin‑Quan Tang Qiu‑Yan Chen Huan‑Xin Lin Yu‑Jing Liang Jin‑Jie Yan Chao Lin Shan‑Shan Guo Li‑Ting Liu Yang Li Hao‑Jun Xie Qing‑Nan Tang Hu Liang Ling Guo Hai‑Qiang Mai | 2019 | 癌症2019，38，9： | 0 |
| 4 | Data analysis guidelines for single‑cell RNA‑seq in biomedical studies and clinical applications显示文摘The application of single-cell RNA sequencing(scRNA-seq)in biomedical research has advanced our understanding of the pathogenesis of disease and provided valuable insights into new diagnostic and therapeutic strategies.With the expansion of capacity for high-throughput scRNA-seq,including clinical samples,the analysis of these huge volumes of data has become a daunting prospect for researchers entering this field.Here,we review the workflow for typical scRNA-seq data analysis,covering raw data processing and quality control,basic data analysis applicable for almost all scRNA-seq data sets,and advanced data analysis that should be tailored to specific scientific questions.While summarizing the current methods for each analysis step,we also provide an online repository of software and wrapped-up scripts to support the implementation.Recommendations and caveats are pointed out for some specific analysis tasks and approaches.We hope this resource will be helpful to researchers engaging with scRNA-seq,in particular for emerging clinical applications. | Min Su Tao Pan Qiu‑Zhen Chen Wei‑Wei Zhou Yi Gong Gang Xu Huan‑Yu Yan Si Li Qiao‑Zhen Shi Ya Zhang Xiao He Chun‑Jie Jiang Shi‑Cai Fan Xia Li Murray J.Cairns Xi Wang Yong‑Sheng Li | 2023 | Military Medical Research2023，10，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员